Publicaciones en colaboración con investigadores/as de University of Eastern Piedmont Amadeo Avogadro (18)

2024

  1. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  2. Correction to: AI is a viable alternative to high throughput screening: a 318-target study (Scientific Reports, (2024), 14, 1, (7526), 10.1038/s41598-024-54655-z)

    Scientific Reports

  3. Multidisciplinary Delphi Consensus on Safety of Combining Transarterial Radioembolization with Yttrium-90 Microspheres with Systemic Anticancer Agents for the Treatment of Liver Malignancy

    Journal of Vascular and Interventional Radiology, Vol. 35, Núm. 9, pp. 1253-1267.e1

  4. Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease

    Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 4

  5. Treatment and outcomes in breast cancer patients: A cross section study from the EUSOMA breast centre network

    European Journal of Cancer, Vol. 196

2023

  1. Comparative analysis of CAR T-cell therapy access for DLBCL patients: associated challenges and solutions in the four largest EU countries

    Frontiers in Medicine, Vol. 10

2021

  1. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

2020

  1. ESTRO IORT Task Force/ACROP recommendations for intraoperative radiation therapy in borderline-resected pancreatic cancer

    Clinical and Translational Radiation Oncology, Vol. 23, pp. 91-99

  2. ESTRO IORT Task Force/ACROP recommendations for intraoperative radiation therapy in unresected pancreatic cancer

    Radiotherapy and Oncology, Vol. 148, pp. 57-64

  3. Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach

    Hepatology, Vol. 72, Núm. 1, pp. 198-212

2019

  1. Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia

    Haematologica, Vol. 104, Núm. 2, pp. 360-369

2018

  1. Richter transformation driven by Epstein–Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia

    Journal of Pathology, Vol. 245, Núm. 1, pp. 61-73

2017

  1. A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)

    Leukemia, Vol. 31, Núm. 1, pp. 107-114

2016

  1. Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors

    Haematologica, Vol. 101, Núm. 8, pp. 959-967

2015

  1. Analysis of heritability and shared heritability based on genome-wide association studies for thirteen cancer types

    Journal of the National Cancer Institute, Vol. 107, Núm. 12

  2. Recurrent mutations refine prognosis in chronic lymphocytic leukemia

    Leukemia, Vol. 29, Núm. 2, pp. 329-336

2014

  1. Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study

    American Journal of Hematology, Vol. 89, Núm. 4, pp. 355-362

2013

  1. Clinical and technical characteristics of intraoperative radiotherapy: Analysis of the ISIORT-Europe database

    Strahlentherapie und Onkologie